Pune-based health-tech startup, LiveHealth has raised $1.1 million from Nexus Venture Partners in the seed round.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.



Health-tech Startup LiveHealth Raises $1.1 Million in Seed Round

Pune-based health-tech startup, LiveHealth has raised $1.1 million from Nexus Venture Partners in the seed round.


AstraZeneca Spinout Viela Bio Fetches $250 M, Pushes Pipeline Autoimmune Drugs in Clinical Study

AstraZeneca has spun out a new inflammation- and autoimmunity-focused biotech, Viela Bio with six molecules from MedImmune. The company has raised up to $250 million in a Series A funding round led by Chinese investor Boyu Capital. Viela Bio Funding.


Shire’s Lanadelumab Gets Priority Review from USFDA for Hereditary Angioedema

Shire’s lanadelumab (SHP643) received Priority Review status from the US FDA for the prevention of attacks in Hereditary Angioedema (HAE) patients.


Shire, Microsoft Came Together to Address Diagnostic Issues in Rare Diseases

Rare diseases biopharma, Shire has collaborated with Microsoft and EURORDIS-Rare Diseases Europe to form a global commission which would address the diagnostic issues for patients living with a rare disease.

Most Popular


7 New Ideas to Start a Healthcare Business in India (2018)

Healthcare in India is showing a gradual progress and there is an abundance of opportunity to create an evolving business by tackling the major challenges of the mass population. Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our observations of the current Indian market, its behavior, challenges, and opportunities.


10 Potential Drugs in Development for Alzheimer’s Disease (2018)

The AD has the worst history of drug candidates’ failures during clinical development. Meager progress has been made in the drug research of AD in the last 15 years. According to Alzheimer’s Association, more than 5.4 million people get affected with the disease in the US which is believed to rise to 16 million by 2050. Here are the ten potential drugs in the late stage of the clinical development for AD in 2018. Total word counts: 1333, Continue reading....

Leave a reply